: AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

AstraZeneca PLC AZNUK:AZN said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-administered flu vaccine. The company said the regulator has accepted its Supplemental Biologics License Application for its Flumist quadrivalent flu vaccine, a needle-free nasal spray. If approved, it would be the first and only such vaccine and would be targeted at adults 18 years and older who would use it at home. “Vaccination rates for children and adults under 50 years of age declined in the 2022-2023 flu season, highlighting a need for more accessible solutions,” said Dr. Ravi Jhaveri, division head of infectious diseases and a professor at Northwestern University School of Medicine, in a statement.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.